Free shipping from 199 € Neutral packaging Analysis reports linked For Research Use Only Free shipping from 199 € Neutral packaging Analysis reports linked For Research Use Only Free shipping from 199 € Neutral packaging Analysis reports linked For Research Use Only
Research area

Metabolic Research

Retatrutide — triple agonist from incretin research

Triple agonist GLP-1 research Incretins Metabolism

Research compound for studies on incretin signaling, receptor pharmacology, and energy metabolism. As Vial (lyophilized) or Pen.

Retatrutide Vial 10 mg – lyophilisiert, Research Use Only | SunPept
Metabolic Research

Retatrutide — Vial

from €150.00 View →
11 Janoshik reports linked
Phase 3 Clinical development
3 Receptor targets
3 Strengths: 10/20/30 mg
Basic research

Triple agonism: three receptors in one molecule

Retatrutide simultaneously activates three metabolically relevant hormone receptors — a unique profile for basic research on energy homeostasis and incretin signaling.

GLP-1 receptor

GLP-1R signaling is investigated in the context of insulin secretion and gastric motility; the receptor pharmacology is extensively documented in the literature.

GIP receptor

GIPR signaling is investigated in the context of insulin secretion and in adipocyte models (Finan et al., Sci Transl Med 2013).

Third receptor axis

In addition to GLP-1R and GIPR, retatrutide addresses a further class B receptor, which is studied mainly in hepatic models of energy expenditure (Coskun et al., Cell Metab 2022).

Adipocyte signaling

In preclinical models, lipid metabolism-related signalling cascades are studied under combined multi-receptor activation.

Products

Metabolic Research — research compounds

As Vial or Pen. Analysis reports shown per product. Shipping to 25 EU countries, 24–48 h after receipt of payment.

Science

Primary literature

Selected peer-reviewed publications on which research in this area is based.

External source

Jastreboff AM et al.

2023 · N Engl J Med

Phase 2 trial of the triple agonist Retatrutide (LY3437943)

External source

Finan B et al.

2013 · Sci Transl Med

Unimolecular dual incretin agonists (preclinical study)

External source

Nauck MA, Meier JJ

2018 · Diabetes Obes Metab

Incretin hormones: Their role in health and disease

Questions & answers

Frequently asked questions

What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that simultaneously activates three related hormone receptors, including GLP-1R and GIPR. The compound is in clinical development (Phase 3). Available at SunPept exclusively as a research compound.
Is Retatrutide a medicinal product?
No. The substance offered by SunPept is a research chemical for scientific laboratory studies — not approved as a medicinal product, not intended for human use.
Which strengths are available?
10 mg, 20 mg, and 30 mg, each as a Vial (lyophilized, incl. 3 ml bacteriostatic water) or as a Pen (substance already dissolved).
How do I store lyophilized Retatrutide?
Storage recommendation: −20 °C, protected from light, in the lyophilized state. Stability after dissolution depends on the substance and is defined in the study protocol.
Research Journal

From the Journal

In-depth articles on compounds and mechanisms in this research area.

Research Use Only

Order for your research now

Research compounds with analysis reports shown per product. Shipping to 25 EU countries, 24–48 h after receipt of payment.

All substances offered on SunPept are intended exclusively for scientific research purposes (Research Use Only / RUO). Not for human or veterinary use. Not approved as a medicinal product. Purchase and use are subject to the applicable legal provisions.

Questions?Message us on Telegram